STOCK TITAN

Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking conferences through September

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Autolus Therapeutics plc (Nasdaq: AUTL) has announced an upcoming investor conference call to discuss data on its AUTO3 program presented at the ESMO Virtual Congress 2020. Key events include participation in the Wells Fargo Virtual Healthcare Conference on September 9, the H.C. Wainwright & Co conference on September 15, and the Cantor Fitzgerald conference on September 17. A detailed investor call regarding AUTO3 will occur on September 18, with Dr. Christian Itin and the clinical team. For additional details, visit Autolus.

Positive
  • None.
Negative
  • None.

LONDON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO3 data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 and to participate in Banking conferences through September:

  • 9 September 2020 – The company will participate in an analyst moderated group meeting at the Wells Fargo Virtual Healthcare Conference at 9.20 am EDT, 2.20 pm BST and will also host virtual one-on-one meetings. A live audio webcast of the fireside chat will be available on the investor relations section of the Company’s website at Autolus. An archived replay will be available for a period of 30 days after the conference.
     
  • 15 September 2020 – The company will present at the H.C. Wainwright & Co 22nd Annual Global Investment Conference at 10.30 am EDT, 3.30 pm BST and will also host virtual one-on-one meetings. A live audio webcast of the presentation will be available on the investor relations section of the Company’s website at Autolus. An archived replay will be available for a period of 30 days after the conference.
     
  • 17 September 2020 – The company will present at the Cantor Fitzgerald Virtual Global Healthcare Conference at 4.00 pm EDT, 9.00 pm BST and will also host virtual one-on-one meetings.
     
  • 18 September 2020 – Dr. Christian Itin, chairman and chief executive officer, along with the AUTO3 clinical team, will host an investor call and webcast at 8.00 am EDT, 1.00 pm BST to discuss a presentation related to its AUTO3 program, the company’s CAR T cell therapy being investigated in the Alexander study, a Phase 1/2 study in relapsed/ refractory diffuse large B cell lymphoma (DLBCL), during the ESMO conference. To listen to the webcast and view the accompanying slide presentation, please go to Autolus.

    The call may also be accessed by dialing (866) 652-5200 for U.S. and Canada callers or (412) 317-6060 for International callers. Please ask to be joined into the Autolus Therapeutics call. An archived replay will be available for a period of 12 months after the call. 
  • 22 September 2020 – The company will participate in a Q&A at the virtual JP Morgan CEO Series Investor Call at 11.00 am EDT, 4.00 pm BST.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.

Contact:

Lucinda Crabtree, PhD
Vice President, Investor Relations and Corporate Communications
+44 (0) 7587 372 619
l.crabtree@autolus.com

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com

FAQ

What is the purpose of Autolus Therapeutics' conference call on September 18, 2020?

The call is to discuss the AUTO3 program and its presentation at the ESMO Virtual Congress 2020.

When will Autolus participate in the Wells Fargo Virtual Healthcare Conference?

Autolus will participate in the conference on September 9, 2020.

Who is hosting the investor call about AUTO3 on September 18, 2020?

Dr. Christian Itin and the AUTO3 clinical team will host the investor call.

What is the significance of the AUTO3 data being presented?

The data is part of Autolus's ongoing research into CAR T cell therapy for lymphoma.

Where can I access the live audio webcast for Autolus' presentations?

The webcast will be available on the investor relations section of the Autolus website.

Autolus Therapeutics plc American Depositary Share

NASDAQ:AUTL

AUTL Rankings

AUTL Latest News

AUTL Stock Data

591.43M
213.36M
18.09%
77.33%
2.35%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
LONDON